Let's not spin it. The result is a shock, the trial failed. Let's not spin it because the people who got it right for all the wrong reasons appear to have won. Let's not spin it because we have lost our money or our profits.
Let's be sad for the people with, and the carers of people with, degenerative neurological conditions who have had their short term hopes for a genuine modifier of these conditions dashed.
Hopefully, it is not the end of PBT2 as a potential treatment, but the road ahead is now longer and harder. Let's hope that the curse of AD and other neurological conditions, has suffered an irrecoverable dent from the efforts of the scientists and believers involved in this project. Let's hope that this unexpected setback is not the end, but another beginning in the fight for an effective treatment.
Most of all let's hope that these results are analysed objectively. It is no good flogging a dead horse, but neither is it prudent to throw out the baby with the bath water.
It has been a pleasure to read and contribute to this forum. Good luck to all those who gave their time and researched fairly and objectively over the years - there is no blame there.
This result is the nature of the scientific method which, hopefully, will prevail in the end.
PBT Price at posting:
$1.04 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)